Elias Jabbour

TL;DR: The discovery of targetable molecular abnormalities and recent studies of targeted therapies, future use of checkpoint inhibitors and other immune therapies such as chimeric antigen receptor T-cells, and maintenance strategies based on the minimal residual disease evaluation represent novel, exciting clinical leads aimed to improve AML outcomes in the near future.

TL;DR: Tametinib, a mitogen‐activated protein kinase kinase 1 (MEK1)/MEK2 inhibitor with activity against multiple myeloid cell lines at low nanomolar concentrations, was evaluated for safety and clinical activity in patients with relapsed/refractory leukemias.

TL;DR: Gene expression profiling of CML at diagnosis for PTGS1 may be useful in predicting imatinib response and in selecting alternate therapy.

TL;DR: Therapy for patients with myelodysplastic syndrome with hypomethylating agents, like decitabine and 5‐azacitidine, has produced favorable results and cytogenetic response patterns and prognostic factors associated with decitABine therapy are analyzed.

TL;DR: The latest studies reporting VOD/SOS risk factors support previously published data, although the importance of patient-related factors, such as acute kidney injury, increased international normalized ratio, female sex (in children), and platelet refractoriness, is given greater emphasis in the recent data.